Novo Nordisk Guidance Implies Cuts to Consensus Sales and Earnings -- Market Talk
Dow Jones
Nov 05
0957 GMT - Novo Nordisk's new guidance implies a 2% sales and 3% EBIT cut to consensus, UBS analyst Matthew Weston writes. However, the focus of the guidance cut will be the implication for growth heading into 2026, he says. The third-quarter headline miss appears relatively modest at first glance, with sales 2% below and EBIT 4% below expectations, he adds. "While expectations were low going into today's results, we expect continued disappointment on the magnitude of the guidance cut, implications for 2026 growth and the ongoing readacross from Novo's unsolicited offer for Metsera." Shares rise 1.4%. (dominic.chopping@wsj.com)
(END) Dow Jones Newswires
November 05, 2025 04:59 ET (09:59 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.